By coating the surfaces of tiny carbon nanotubes with monoclonal antibodies, biochemists and engineers at Jefferson Medical College and the University of Delaware have teamed up to detect cancer cells in a tiny drop of water. The work is aimed at developing nanotube-based biosensors that can spot cancer cells circulating in the blood from a treated tumor that has returned or from a new cancer.
The researchers, led by Eric Wickstrom, Ph.D., professor of biochemistry and molecular biology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and at the Kimmel Cancer Center at Jefferson, and Balaji Panchapakesan, Ph.D., assistant professor of electrical engineering at the University of Delaware in Newark, present their findings November 17, 2005 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
The group took advantage of a surge in electrical current in nanotube-antibody networks when cancer cells bind to the antibodies. They placed microscopic carbon nanotubes between electrodes, and then covered them with monoclonal antibodies so-called guided protein missiles that home in on target protein "antigens" on the surface of cancer cells. The antibodies were specific for insulin-like growth factor 1 receptor (IGF1R), which is commonly found at high levels on cancer cells. They then measured the changes in electrical current through the antibody-nanotube combinations when two different types of breast cancer cells were applied to the devices.
The researchers found that the increase in current through the antibody-nanotube devices was proportional to the number of receptors on the cancer cell surfaces. One type, human BT474 breast cancer cells, which do not respond to estrogen, had moderate IGF1R levels, while the other type, MCF7, which needs estrogen to grow, had high IGF1R levels.
The BT474 cancer cells, which had less IGF1R on their surfaces, caused a three-fold Page: 1 2 3 Related medicine news :1
. Fat protein cuts blood vessel inflammation, may help heart, Jefferson scientists find2
. Jefferson pharmacologist says biomarker discovery bodes well for better cancer diagnostics3
. Jefferson immunology researchers show blood-brain barrier damage could affect MS severity4
. Jefferson scientists find that plavix appears to be safe during and after heart bypass5
. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations6
. Jefferson scientists find that drug-eluting stents are disappointing in bypass grafts -- sometimes7
. Empathy skills must be given a high priority in medical education, says Jefferson author8
. Natural, soy-based substance might help fight MS, Jefferson neuroscientists find9
. Blood pressure drugs could help halt pancreatic cancer spread, Jefferson researchers find10
. Obesity tied to higher risk of complications in spinal surgery, Jefferson neurosurgeon finds11
. Jefferson Orthopaedic surgeons leading international study of timing of spinal surgery